Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time

@article{Dhondt2018DiscoveryAV,
  title={Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time},
  author={Bert Dhondt and Elise De Bleser and Tom Claeys and Sarah Buelens and Nicolaas Lumen and Jo Vandesompele and Anneleen Beckers and Val{\'e}rie Fonteyne and Kim Van der Eecken and Aur{\'e}lie De Bruycker and J{\'e}r{\^o}me Paul and Pierre Gramme and Piet Ost},
  journal={World Journal of Urology},
  year={2018},
  pages={1-8}
}
PurposePatients with oligometastatic prostate cancer (PC) may benefit from metastasis-directed therapy (MDT), delaying disease progression and the start of palliative systemic treatment. However, a significant proportion of oligometastatic PC patients progress to polymetastatic PC within a year following MDT, suggesting an underestimation of the metastatic load by current staging modalities. Molecular markers could help to identify true oligometastatic patients eligible for MDT.MethodsPatients… Expand
Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review
TLDR
The aim of the present narrative review is to report the current state of the art on the solidity of liquid biopsy-related analytes such as CTCs, cfDNA, miRNA and epi-miRNA and their reliability as biomarkers in the clinics for the identification of true-oligometastatic patients and to provide a benchmark for their further clinical implementation. Expand
Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases
TLDR
A median PFS of 16 months was attained after SBRT for patients with PSMA-PET positive oligometastatic lymph nodes from prostate cancer, and higher pre-SBRT PSA, younger age and extrapelvic location were found to be predictors of shorter PFS. Expand
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
TLDR
20 international experts including 19 members of the European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer OligoCare project developed a comprehensive system for characterisation and classification of oligometastatic disease. Expand
Prognostic and Predictive Biomarkers in Oligometastatic Disease
TLDR
Prognostic and predictive biomarkers of oligometastatic disease are strongly needed to identify patient candidates most likely to gain survival benefit from local therapies and to aid in the incorporation of ablative treatments in the context of existing systemic therapies. Expand
Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer
TLDR
Oligo-MBC defined as MBC limited to 1-3 metastases was associated with favorable OS and progression-free survival in OMBC, independent of local therapy of the primary tumor. Expand
Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries
TLDR
Most trials address local ablative treatments both for prostate and/or metastases, typically by radiotherapy, and several attempts to determine the benefit of adding systemic therapy. Expand
Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies
TLDR
An overview of epigenetic biomarkers current state is provided based on a comprehensive review of the relevant literature in blood-based liquid biopsies and challenges/limitations of this new and growing field of cancer biomarkers. Expand
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
TLDR
Consensus was reached that OMD is largely independent of primary tumour, metastatic location and the presence or length of a disease-free interval, supporting both synchronous and metachronous OMD. Expand
Oligometastatic prostate cancer: The game is afoot.
TLDR
The aim of this review is to shed light on the clinical scenario of prostate cancer patients with limited metastatic disease burden and highlight the role of MDT strategies in this setting. Expand
Developments in oligometastatic hormone-sensitive prostate cancer
TLDR
A special issue in the Journal on Developments in oligometastatic hormone-sensitive prostate cancer is presented and preliminary data suggest that tissue microRNAs (miRNAs), small 18–24 nucleotide RNAs that regulate gene expression, may drive metastatic competency by adaptive communication between cancer cells and their local and distant environment. Expand
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
MicroRNA Expression Characterizes Oligometastasis(es)
Background Cancer staging and treatment presumes a division into localized or metastatic disease. We proposed an intermediate state defined by ≤5 cumulative metastasis(es), termed oligometastases. InExpand
Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs
TLDR
Oligo- and poly- metastasis are distinct entities at the clinical and molecular level and prioritized microRNAs distinguished HRP from LRP and were associated with rate of metastatic progression and survival in an independent validation dataset. Expand
Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology
TLDR
Current developments in molecular imaging have allowed for improved detection of metastatic prostate cancer allowing for more accurate staging of patients with oligometastatic disease and future development of biologic markers may assist in defining the oligometricastatic state and determining prognosis. Expand
Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
TLDR
Three integrated molecular subtypes of colorectal cancer liver metastasis are identified, which complement clinical risk stratification to distinguish the subset of oligometastatic patients and provide a framework for integrated classification and treatment of metastasis. Expand
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
TLDR
ADT-free survival was longer with MDT than with surveillance alone for oligorecurrent PCa, suggesting that MDT should be explored further in phase III trials. Expand
Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer
Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCa). Recent findings ThreeExpand
Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
TLDR
MDT is a promising approach for oligometastatic PCa recurrence, but the low level of evidence generated by small case series does not allow extrapolation to a standard of care, and requires validation in randomised controlled trials. Expand
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
TLDR
The ORIOLE trial is the first randomized, non-blinded Phase II interventional study in the North America evaluating the safety and efficacy of SABR in oligometastatic hormone-sensitive prostate cancer and leading-edge laboratory and imaging correlates will provide unique insight into the effects of S ABR on the oligometricastatic state. Expand
Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.
TLDR
A systematic review and meta-analysis of reported predictors of positive 68Ga-PSMA PET and corresponding sensitivity and specificity profiles found that this new test provides excellent rates of detection of cancer spread in late-stage prostate cancer. Expand
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
TLDR
Randomised trials are essential to determine the value of extirpative treatment for oligometastatic bony metastases due to PC and evidence is found of a clear prognostic gradient according to number of bONY metastatic sites. Expand
...
1
2
3
...